Licorice Root Extract for Hyperpigmentation: Glabridin, Licochalcone A, and Multi-Pathway Inhibition Science

Licorice root extract is one of the oldest documented skin-brightening agents in the world of topical cosmetics, with roots in traditional Ayurvedic and Chinese medicine stretching back thousands of years. Modern biochemical research has validated what traditional healers observed empirically: certain polar compounds isolated from Glycyrrhiza glabra are extraordinarily effective at reducing visible hyperpigmentation. This article breaks down the key active constituents — glabridin, licochalcone A, isoliquiritigenin, and glabrene — and explains why licorice root extract is increasingly appearing in premium brightening formulations in 2026.

Unlike single-mechanism actives such as kojic acid or hydroquinone, licorice root extract addresses melanogenesis through multiple simultaneous pathways. This multi-target strategy makes it particularly effective for stubborn, recalcitrant pigmentation that resists single-pathway inhibition — a challenge every formulator building brightening products eventually faces.

Botanical Background: Glycyrrhiza glabra

Glycyrrhiza glabra — commonly known as licorice — is a leguminous plant native to the Mediterranean region, Central Asia, and parts of China. Its root contains a complex mixture of triterpenoid saponins (notably glycyrrhizin), flavonoids, coumarins, and phenolic compounds. The brightening activity of greatest cosmetic interest is concentrated in the flavonoid fraction, particularly the chalcones and isoflavans.

The primary extract used in topical formulations is deglycyrrhizinated licorice root extract (DGLE), where the glycyrrhizin — the compound responsible for licorice’s sweet taste and its mineralocorticoid-like side effects when ingested — has been substantially removed. This makes DGLE safe for long-term cosmetic use without the systemic hormonal concerns associated with whole-root extract.

Glabridin: The Flagship Tyrosinase Inhibitor

Glabridin is an isoflavan — a subclass of flavonoids — that constitutes approximately 1–4% of the total flavonoid fraction in licorice root extract. It is considered the primary driver of the extract’s skin-brightening activity and has been the subject of extensive in vitro and in vivo research.

In vitro enzyme kinetic studies demonstrate that glabridin is a mixed-type inhibitor of mushroom tyrosinase, with a Ki value reported between 1.6–7.8 x 10^-5 M depending on assay conditions. More importantly, it exhibits significantly greater selectivity for human tyrosinase than many synthetic alternatives, reducing off-target effects in the skin.

The structural basis for glabridin’s tyrosinase inhibition lies in its ability to chelate the binuclear copper center at the enzyme’s active site. The catechol B-ring and the lipophilic isoflavan scaffold together create a high-affinity binding interaction that competes with the natural substrate L-tyrosine.

Beyond direct enzyme inhibition, glabridin demonstrates potent antioxidant activity via direct radical scavenging (DPPH IC50 = 18 uM) and upregulation of cellular antioxidant defenses through NRF2 pathway activation. This is significant because reactive oxygen species (ROS) are critical signaling molecules in UV-induced melanogenesis — by quenching ROS, glabridin interrupts one of the primary triggers for melanin overproduction.

Licochalcone A: Dual Anti-Inflammatory and Pigment-Regulating Activity

Licochalcone A is a unique retrochalcone found predominantly in the species Glycyrrhiza inflata, though it is present in smaller amounts in other licorice species. Its structure differs from typical chalcones by the presence of a prenyl group and oxidized substituents that confer unusual biological properties.

Licochalcone A modulates pigmentation through two distinct mechanisms that are particularly relevant to post-inflammatory hyperpigmentation (PIH):

• Inflammatory cascade suppression: Licochalcone A inhibits NF-kB signaling and reduces prostaglandin E2 (PGE2) and leukotriene production in keratinocytes and dermal fibroblasts. Since inflammatory mediators are potent stimulators of melanocyte dendricity and tyrosinase activity, this anti-inflammatory effect contributes indirectly but significantly to pigment reduction.
• Direct MITF downregulation: At concentrations of 10-50 uM, licochalcone A reduces microphthalmia-associated transcription factor (MITF) expression in cultured melanocytes, attenuating the transcription of TYR, TYRP1, and DCT — the three key genes encoding melanogenic enzymes.

This dual mechanism makes licochalcone A especially valuable in formulations targeting acne-induced or eczema-induced post-inflammatory hyperpigmentation, where inflammation is the proximate driver of melanin overproduction.

Isoliquiritigenin: PAR-2 Inhibition and Melanosome Transfer Blockade

Isoliquiritigenin (ISL) is a chalcone with a distinctive scaffold that gives it a different biological profile from the isoflavans. Research published in the Journal of Dermatological Science demonstrated that ISL acts as a protease-activated receptor-2 (PAR-2) antagonist, reducing the transfer of melanosomes from melanocytes to surrounding keratinocytes.

This mechanism of melanosome transfer inhibition is shared with niacinamide (vitamin B3) but operates through a distinct molecular target. The clinical implication: formulations combining isoliquiritigenin-containing licorice extract with niacinamide may achieve more complete pigment reduction than either ingredient alone, since they target different steps in the pigment-dissemination pathway.

ISL also exhibits direct tyrosinase inhibition, though less potent than glabridin. Its value in a formulation lies in the breadth of its activity across multiple melanogenesis pathways.

Clinical Evidence: What the Studies Show

A 2019 double-blind, randomized controlled trial published in the Journal of Cosmetic Dermatology evaluated a topical formulation containing 0.5% licorice extract (standardized to 2.5% glabridin) in 42 subjects with mild-to-moderate melasma. After 12 weeks of twice-daily application, the treatment group showed a statistically significant (p < 0.01) mean improvement in MASI (Melasma Area and Severity Index) score of 38%, compared to 12% in the placebo group.

A 2023 in vivo study using reflectance confocal microscopy showed that a 4-week application of a glabridin-containing serum reduced melanin content in the basal epidermis by approximately 27% compared to baseline, with no reported adverse events. The study noted particular efficacy in the dermal-epidermal junction region, which is historically difficult to target with topical agents.

Licorice extract has also demonstrated synergistic effects when combined with other brightening actives. An in vitro combination study showed that a 1:1 ratio of glabridin and alpha-arbutin produced approximately 2.3x greater tyrosinase inhibition than either compound alone at equivalent concentrations — a finding with direct formulation implications.

Formulation Considerations

Effective incorporation of licorice root extract requires attention to several formulation variables:

• pH compatibility: Glabridin is most stable in the pH range of 4.0-6.5. Strongly acidic formulations (pH < 3.5) or highly alkaline preparations (pH > 8) will degrade the active flavonoids over time.
• Delivery system: Glabridin is lipophilic. Oil-in-water emulsions with a lipid phase of at least 15-20% provide good partitioning into the stratum corneum. For deeper dermal delivery, liposomal or nanoemulsion carriers significantly enhance penetration to the viable epidermis.
• Concentration: Effective cosmetic concentrations range from 0.5-2% for standardized extract (containing 2.5-10% glabridin by weight). Higher concentrations do not linearly improve efficacy and may increase the risk of contact sensitization in predisposed individuals.
• Preservation: The phenolic compounds in licorice extract provide some inherent antimicrobial activity, but standard cosmetic preservatives remain necessary, particularly in aqueous formulations.
• Synergistic combinations: Strong evidence supports pairing licorice extract with alpha-arbutin, niacinamide, tranexamic acid, or vitamin C. These combinations target complementary steps in melanogenesis and often produce clinically meaningful improvements over single-ingredient use.

Regulatory Status

Licorice root extract in its deglycyrrhizinated form is approved for cosmetic use in all major markets, including the European Union (INCI: Glycyrrhiza Glabra Root Extract, listed in CosIng), the United States (FDA cosmetics ingredient listing), and most Asian markets including ASEAN member states. It is not subject to the usage restrictions that apply to hydroquinone in several jurisdictions.

As of 2026, licorice extract and its standardized fractions (glabridin, licochalcone A) appear on the INCI lists of multiple high-profile brightening brands globally, cementing its position as a scientifically validated, commercially proven skin-brightening ingredient for formulators targeting the Southeast Asian market where melanin-rich skin types are prevalent and demand for effective pigment correction is highest.